CL2016002463A1 - Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de tales composiciones. - Google Patents
Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de tales composiciones.Info
- Publication number
- CL2016002463A1 CL2016002463A1 CL2016002463A CL2016002463A CL2016002463A1 CL 2016002463 A1 CL2016002463 A1 CL 2016002463A1 CL 2016002463 A CL2016002463 A CL 2016002463A CL 2016002463 A CL2016002463 A CL 2016002463A CL 2016002463 A1 CL2016002463 A1 CL 2016002463A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- solid pharmaceutical
- pharmaceutical compositions
- biopterin derivatives
- preparing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical class N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940102223 injectable solution Drugs 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14162727.3A EP2926805B1 (en) | 2014-03-31 | 2014-03-31 | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002463A1 true CL2016002463A1 (es) | 2017-01-27 |
Family
ID=50389975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002463A CL2016002463A1 (es) | 2014-03-31 | 2016-09-29 | Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de tales composiciones. |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US9895372B2 (enExample) |
| EP (2) | EP2926805B1 (enExample) |
| JP (3) | JP6552515B2 (enExample) |
| KR (1) | KR102374500B1 (enExample) |
| CN (2) | CN113521017A (enExample) |
| AU (2) | AU2015239736B2 (enExample) |
| CA (1) | CA2938267C (enExample) |
| CL (1) | CL2016002463A1 (enExample) |
| CY (1) | CY1117881T1 (enExample) |
| DK (1) | DK2926805T3 (enExample) |
| ES (1) | ES2586945T3 (enExample) |
| HR (1) | HRP20160802T1 (enExample) |
| HU (1) | HUE030221T2 (enExample) |
| IL (1) | IL248090B (enExample) |
| MX (1) | MX377919B (enExample) |
| MY (1) | MY180844A (enExample) |
| PE (1) | PE20161253A1 (enExample) |
| PH (1) | PH12016501519A1 (enExample) |
| PL (1) | PL2926805T3 (enExample) |
| PT (1) | PT2926805T (enExample) |
| RS (1) | RS54973B1 (enExample) |
| RU (1) | RU2694368C2 (enExample) |
| SA (1) | SA516371933B1 (enExample) |
| SG (1) | SG11201606151SA (enExample) |
| SI (1) | SI2926805T1 (enExample) |
| SM (1) | SMT201600246B (enExample) |
| WO (1) | WO2015150294A1 (enExample) |
| ZA (1) | ZA201605271B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6382997B2 (ja) | 2014-02-07 | 2018-08-29 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
| EP2926805B1 (en) | 2014-03-31 | 2016-05-18 | Vasopharm GmbH | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |
| JP2016168783A (ja) * | 2015-03-13 | 2016-09-23 | 株式会社東芝 | 記録装置、記録方法、及び記録媒体 |
| US12171766B2 (en) | 2021-12-03 | 2024-12-24 | Verinos Operations Gmbh | Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury |
| WO2019046849A1 (en) * | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| JP6565103B2 (ja) * | 2017-09-06 | 2019-08-28 | 株式会社昭和冷凍プラント | 香気成分含有水溶液を含む液状製品の製造方法 |
| KR20220070477A (ko) * | 2019-09-25 | 2022-05-31 | 피티씨 테라퓨틱스 엠피, 인크. | 고페닐알라닌혈증 치료 방법 |
| CA3235704A1 (en) | 2021-12-03 | 2023-06-08 | Verinos Operations Gmbh | Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury |
| EP4539850A1 (en) | 2022-05-06 | 2025-04-23 | VeriNOS operations GmbH | Methods of treating patients suffering from a disease condition or disorder that is associated with an increased glutamate level |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922713A (en) * | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
| DE59703603D1 (de) | 1997-10-06 | 2001-06-28 | Ernst Werner | Pteridinderivate als NO Synthase-Hemmer |
| US6803046B2 (en) * | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
| WO2005037286A1 (en) * | 2003-03-25 | 2005-04-28 | Vasopharm Biotech Gmbh | Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia |
| JP2007536210A (ja) * | 2003-11-17 | 2007-12-13 | メルック・エプロバ・アクチエンゲゼルシヤフト | （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形 |
| WO2005107759A1 (ja) * | 2004-05-11 | 2005-11-17 | Daiichi Asubo Pharma Co., Ltd. | Ｂｈ４反応性高フェニルアラニン血症治療剤 |
| SE0401826D0 (sv) | 2004-07-09 | 2004-07-09 | Trimble Ab | Method of preparing a winding for an n-phase motor |
| EP2436379A1 (en) * | 2004-11-17 | 2012-04-04 | BioMarin Pharmaceutical Inc. | Stable tablet formulation |
| EP1669355A1 (en) * | 2004-12-02 | 2006-06-14 | Vasopharm Biotech GmbH | Aminotetrahydropteridines and processes for manufacture thereof |
| DK3461503T3 (da) * | 2007-04-11 | 2022-02-14 | Biomarin Pharm Inc | Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder |
| EP2140731A2 (de) | 2007-04-24 | 2010-01-06 | Osram Gesellschaft mit Beschränkter Haftung | Schaltungsanordnung zur zündung und zum betrieb einer entladungslampe |
| ES2736730T3 (es) * | 2008-08-12 | 2020-01-07 | Orpha Swiss Gmbh | Forma de administración farmacéutica que contiene tetrahidrobiopterina |
| EP2680848A4 (en) * | 2011-03-01 | 2014-11-05 | Rubicon Res Private Ltd | STABLE TETRAHYDROBIOPTERINE COMPOSITIONS |
| US9006289B2 (en) * | 2011-08-30 | 2015-04-14 | Fresenius Kabi Usa, Llc | Levothyroxine formulations |
| EP2926805B1 (en) * | 2014-03-31 | 2016-05-18 | Vasopharm GmbH | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |
-
2014
- 2014-03-31 EP EP14162727.3A patent/EP2926805B1/en active Active
- 2014-03-31 RS RS20160595A patent/RS54973B1/sr unknown
- 2014-03-31 ES ES14162727.3T patent/ES2586945T3/es active Active
- 2014-03-31 PT PT141627273T patent/PT2926805T/pt unknown
- 2014-03-31 DK DK14162727.3T patent/DK2926805T3/en active
- 2014-03-31 HU HUE14162727A patent/HUE030221T2/en unknown
- 2014-03-31 PL PL14162727.3T patent/PL2926805T3/pl unknown
- 2014-03-31 SI SI201430042A patent/SI2926805T1/sl unknown
-
2015
- 2015-03-30 MX MX2016012784A patent/MX377919B/es unknown
- 2015-03-30 CN CN202110640860.1A patent/CN113521017A/zh active Pending
- 2015-03-30 KR KR1020167025896A patent/KR102374500B1/ko active Active
- 2015-03-30 JP JP2016556270A patent/JP6552515B2/ja active Active
- 2015-03-30 US US14/913,665 patent/US9895372B2/en active Active
- 2015-03-30 AU AU2015239736A patent/AU2015239736B2/en active Active
- 2015-03-30 CA CA2938267A patent/CA2938267C/en active Active
- 2015-03-30 EP EP15715697.7A patent/EP3125864A1/en not_active Withdrawn
- 2015-03-30 WO PCT/EP2015/056824 patent/WO2015150294A1/en not_active Ceased
- 2015-03-30 PE PE2016001818A patent/PE20161253A1/es unknown
- 2015-03-30 SG SG11201606151SA patent/SG11201606151SA/en unknown
- 2015-03-30 RU RU2016141449A patent/RU2694368C2/ru active
- 2015-03-30 CN CN201580017915.6A patent/CN106572976A/zh active Pending
- 2015-03-30 MY MYPI2016702995A patent/MY180844A/en unknown
-
2016
- 2016-07-06 HR HRP20160802TT patent/HRP20160802T1/hr unknown
- 2016-07-26 SM SM201600246T patent/SMT201600246B/it unknown
- 2016-07-29 ZA ZA2016/05271A patent/ZA201605271B/en unknown
- 2016-08-01 PH PH12016501519A patent/PH12016501519A1/en unknown
- 2016-08-04 CY CY20161100768T patent/CY1117881T1/el unknown
- 2016-09-27 IL IL24809016A patent/IL248090B/en active IP Right Grant
- 2016-09-27 SA SA516371933A patent/SA516371933B1/ar unknown
- 2016-09-29 CL CL2016002463A patent/CL2016002463A1/es unknown
-
2017
- 2017-05-02 US US15/584,890 patent/US10016431B2/en active Active
-
2018
- 2018-06-08 US US16/003,374 patent/US10493075B2/en active Active
-
2019
- 2019-07-02 JP JP2019123306A patent/JP6879582B2/ja active Active
- 2019-10-21 US US16/659,401 patent/US10925877B2/en active Active
-
2020
- 2020-06-12 AU AU2020203880A patent/AU2020203880B2/en active Active
-
2021
- 2021-01-20 US US17/153,749 patent/US11717522B2/en active Active
- 2021-04-22 JP JP2021072278A patent/JP7178731B2/ja active Active
-
2023
- 2023-07-20 US US18/224,515 patent/US12458644B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002463A1 (es) | Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| MX2019002356A (es) | Compuestos de biarilo utiles como inmunomoduladores. | |
| MX389349B (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| CL2017001046A1 (es) | Inhibidoes del bromodominio | |
| MX2013012896A (es) | Compuestos novedosos como moduladores de proteina cinasas. | |
| GT201700234A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CR20170384A (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
| BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
| UY36950A (es) | Compuestos útiles como inhibidores de la interacción proteína-proteína pd-1/pd-l1 y cd80/pd-l1 y composiciones que los contienen | |
| UY36741A (es) | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales | |
| CL2017000742A1 (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| GT201400036A (es) | Compuestos y composiciones como inhibidores de la quinasa c - kit | |
| UY37645A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| EA201692003A1 (ru) | Макроциклические производные пиримидина | |
| MX2015015534A (es) | Derivado de fenol y metodo de preparacion y uso en la medicina del mismo. | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112015029989A2 (pt) | Uso de dianidrogalactitol e análogos e derivados do mesmo para tratar glioma maligno recorrente ou tumor cerebral secundário progressivo | |
| ECSP16074478A (es) | Compuestos novedosos | |
| CL2017001112A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| EA201892219A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| EA201892216A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| DOP2016000253A (es) | Nuevos compuestos | |
| GT201700058A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| MX384798B (es) | Piridinona dicarboxamida para uso como inhibidores de bromodominio. | |
| MX391152B (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. |